How Safe Is SLIT? Sublingual Immunotherapy Safety in Context

The evidence indicates SLIT carries a lower risk of systemic reactions than allergy shots, which is the most meaningful safety distinction between the two. Because sublingual immunotherapy keeps the allergen in contact with the oral lining rather than injecting it into tissue, reactions tend to stay local. Systemic reactions affect fewer than 0.1 percent of patients in our program, and no SLIT fatality has been reported worldwide, whereas injected immunotherapy is associated with a higher systemic-reaction rate. That said, it is more accurate to describe this as a difference in risk profile than to declare shots inferior. Allergy shots have a long, strong evidence base and remain an effective and appropriate option for many people. The lower systemic risk of SLIT is one factor among several, including efficacy, convenience, and your specific allergens, that you and your provider weigh together when choosing a treatment.

The main safety considerations with SLIT fall into a few categories. Most common are mild local reactions, itching of the mouth, throat, or ears, which affect roughly 40.8 percent of patients and usually ease over the early weeks. Less common are mild stomach effects. Uncommon are systemic reactions, affecting fewer than 0.1 percent of patients in our program, which involve symptoms beyond the mouth such as hives or wheezing and warrant medical contact. Exceptionally rare is anaphylaxis, estimated near 1 per 100 million doses, with no SLIT fatality reported worldwide. There are also contraindications: uncontrolled or severe asthma and eosinophilic esophagitis. The practical safeguards, a supervised first dose and a possible epinephrine prescription, exist to manage the rare serious risks. Understanding this layered picture, common and mild at the base, rare and serious at the top, is the best way to gauge how safe SLIT is for you.

FDA-approved sublingual immunotherapy tablets carry a boxed warning because the FDA requires one for any product with a theoretical risk of severe allergic reactions, regardless of how rarely those reactions actually occur in trials. It is a precautionary regulatory measure, not a response to observed deaths. The real-world safety data are reassuring: anaphylaxis is estimated near 1 per 100 million doses, and no SLIT fatality has been reported worldwide. The warning also drives sensible practices such as a supervised first dose and keeping an epinephrine auto-injector available. Allergy drops are compounded at a specialty pharmacy for each patient. The FDA does not review compounded products for safety or efficacy, so the tablet labeling does not apply directly to drops, although the same precautions are reasonable. The boxed warning is best read as appropriate caution layered on top of a genuinely strong safety record.

Yes, SLIT is generally taken at home after a first dose that is often supervised. This home-based model is permitted precisely because the safety profile is favorable: most reactions are mild and local, systemic reactions are uncommon at fewer than 0.1 percent of patients in our program, and no SLIT fatality has been reported worldwide. The supervised first dose lets a clinician confirm that any initial reaction is limited to the expected mild local effects before you continue dosing on your own. Keeping an epinephrine auto-injector accessible during the early weeks is a sensible precaution. Ongoing provider oversight remains part of safe treatment even when dosing happens at home, so you have a point of contact if reactions persist, worsen, or spread beyond the mouth. Your provider will explain exactly how the first dose and home dosing are handled in your program.